Skip to Content

Gefitinib Dosage

Applies to the following strength(s): 250 mg

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Non-Small Cell Lung Cancer

250 mg orally with or without food

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

Higher doses have been reported not to give a better response and to cause an increase in toxicity.


Patients with poorly tolerated diarrhea or skin reactions may be successfully managed by providing up to 14 days of therapy interruption. This may be followed by reinstatement of the 250 mg daily dose.

If acute onset or worsening of pulmonary symptoms occur, therapy should be interrupted and a immediate investigation of the symptoms should occur. If interstitial lung disease is confirmed, gefitinib should be discontinued and treatment should be initiated.

Onset of new eye symptoms such as pain should be medically evaluated and managed appropriately. This includes interruption of therapy and removal of an aberrant eyelash if present. After the symptoms and eye changes have resolved, a decision should be made concerning restarting of the 250 mg daily dose.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available.